Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1/A registration statement with the Securities and Exchange Commission (SEC) on October 28, 2024. The filing pertains to the offering of up to 8,650,520 shares of common stock, alongside an equal number of pre-funded warrants to purchase common stock, and the shares issuable upon the exercise of such pre-funded warrants. The offering is being conducted on a best-efforts basis by Spartan Capital Securities, LLC, which is acting as the exclusive placement agent. The offering is expected to close one business day following its commencement, with the securities being delivered on a delivery versus payment basis. Virpax has agreed to pay Spartan Capital a...Show More

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1/A registration statement with the Securities and Exchange Commission (SEC) on October 28, 2024. The filing pertains to the offering of up to 8,650,520 shares of common stock, alongside an equal number of pre-funded warrants to purchase common stock, and the shares issuable upon the exercise of such pre-funded warrants. The offering is being conducted on a best-efforts basis by Spartan Capital Securities, LLC, which is acting as the exclusive placement agent. The offering is expected to close one business day following its commencement, with the securities being delivered on a delivery versus payment basis. Virpax has agreed to pay Spartan Capital a cash fee of 2.5% of the gross proceeds from the offering. The company has also agreed to a 30-day lock-up period for itself and a 90-day lock-up period for its executive officers and directors, during which they will not sell any shares without the placement agent's consent. The proceeds from the offering are intended to fund ongoing development activities for Virpax's clinical trial for Probudur, working capital, and other general corporate purposes. The common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX', but there are no plans to list the pre-funded warrants. The offering is subject to various selling restrictions in different jurisdictions, including the European Economic Area, the United Kingdom, Canada, Israel, Hong Kong, Singapore, Japan, Dubai International Financial Centre, Australia, and Switzerland.